Related Experiment Video
Updated: Mar 21, 2026
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Altered DNA Methyltransferase Expression in Pulmonary Large-Cell Neuroendocrine Carcinoma: Pilot Experimental Data
Adam Put1,2, Katerina Smesny Trtkova1,2,3, Marcel Mittak1,2
1Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czechia.
Introduction:
Large cell neuroendocrine carcinoma (LCNEC) is a subtype of non-small-cell lung carcinoma with poorly understood methylation characteristics, including the activity of DNA methyltransferases. Despite the pivotal role of DNA methyltransferases in epigenetic regulation, their expression profile in LCNEC remains unexplored. This study represents the first effort to evaluate the expression of DNMT1, DNMT3A, and DNMT3B genes in patients with LCNEC.
Materials And Methods:
We performed quantitative expression analyses of DNMT1, DNMT3A, and DNMT3B on formalin-fixed, paraffin-embedded tissue samples obtained from LCNEC patients. Normal lung tissues (n = 4) from healthy patients served as controls to determine differential expression levels.
Results:
The analysis revealed upregulation of both DNMT1 and DNMT3A compared to control normal lung tissue. In addition, normalized expression values of DNMT3B were reduced compared to the analyzed DNMT1 and DNMT3A.
Conclusion:
In this exploratory pilot of 18 LCNEC cases, DNMT1 and DNMT3A transcripts were frequently higher relative to a normal-lung calibrator, while DNMT3B results were inconclusive due to technical limitations and small sample size. These descriptive findings warrant validation in larger, isoform-resolved cohorts before clinical inference. Future research should prioritize investigating these DNA methyltransferases to explore their therapeutic implications. Moreover, future research should also aim to detect and characterize individual DNMT3B isoforms in LCNEC patients to further elucidate their specific contributions to the pathology of the disease.
Insights
This study found increased expression of DNA methyltransferases 1 and 3A (DNMT1 and DNMT3A) in large cell neuroendocrine carcinoma (LCNEC) lung cancer. Further research is needed to confirm DNMT3B findings and explore therapeutic potential.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Large cell neuroendocrine carcinoma (LCNEC) is a lung cancer subtype with poorly understood DNA methylation patterns.
- DNA methyltransferases (DNMTs) are crucial for epigenetic regulation, but their expression in LCNEC is largely unknown.
- This study is the first to investigate DNMT1, DNMT3A, and DNMT3B gene expression in LCNEC patients.
Purpose of the Study:
- To evaluate the expression levels of DNMT1, DNMT3A, and DNMT3B genes in LCNEC.
- To compare DNMT expression in LCNEC tissues with normal lung tissues.
Main Methods:
- Quantitative expression analysis of DNMT1, DNMT3A, and DNMT3B.
- Utilized formalin-fixed, paraffin-embedded tissue samples from LCNEC patients.
- Compared expression levels against normal lung tissues from healthy individuals.
Main Results:
- DNMT1 and DNMT3A gene expression was found to be upregulated in LCNEC compared to normal lung tissue.
- Normalized expression values for DNMT3B were reduced relative to DNMT1 and DNMT3A.
- DNMT3B results were inconclusive due to technical limitations and a small sample size.
Conclusions:
- DNMT1 and DNMT3A transcripts were frequently elevated in LCNEC cases compared to normal lung tissue.
- Further validation in larger cohorts is necessary to confirm DNMT3B findings and clinical relevance.
- Investigating DNMTs in LCNEC may reveal potential therapeutic targets and requires isoform-specific analysis for DNMT3B.
